US 12,274,780 B2
Method of treating osteoarthritis
Yoshinari Kumagai, Foster City, CA (US); Dawn McGuire, Orinda, CA (US); Meghan Miller, Antioch, CA (US); and David Rosen, New Braunfels, TX (US)
Assigned to OrthoTrophix, Inc., Oakland, CA (US)
Filed by ORTHOTROPHIX, INC., Oakland, CA (US)
Filed on Nov. 2, 2021, as Appl. No. 17/517,533.
Application 17/517,533 is a continuation of application No. 16/586,516, filed on Sep. 27, 2019, abandoned.
Claims priority of provisional application 62/838,712, filed on Apr. 25, 2019.
Claims priority of provisional application 62/811,366, filed on Feb. 27, 2019.
Claims priority of provisional application 62/787,881, filed on Jan. 3, 2019.
Claims priority of provisional application 62/775,056, filed on Dec. 4, 2018.
Prior Publication US 2022/0047501 A1, Feb. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61B 5/00 (2006.01); A61B 5/055 (2006.01); A61B 5/103 (2006.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01); A61P 19/02 (2006.01); C07K 14/47 (2006.01)
CPC A61K 9/0019 (2013.01) [A61B 5/055 (2013.01); A61B 5/103 (2013.01); A61B 5/4504 (2013.01); A61B 5/4514 (2013.01); A61B 5/4528 (2013.01); A61B 5/4585 (2013.01); A61K 38/16 (2013.01); A61K 38/1709 (2013.01); A61P 19/02 (2018.01); C07K 14/47 (2013.01); A61B 5/4824 (2013.01)] 4 Claims
 
1. A method of delaying or reducing pathological bone shape change of a subchondral bone in a joint of a patient having osteoarthritis, comprising:
(i) obtaining a first image of the subchondral bone using magnetic resonance imaging (MRI), and measuring three-dimensional (3D) bone shape of the subchondral bone from the first MRI image, thereby diagnosing pathological bone shape change of the subchondral bone and osteoarthritis progression in the joint;
(ii) administering by local injection into the joint a therapeutically effective amount of a formulation comprising a pharmaceutically active peptide set forth in SEQ ID NO: 1, and a pharmaceutically acceptable, injectable carrier;
(iii) obtaining a second image of the subchondral bone using MRI, and measuring 3D bone shape of the subchondral bone from the second MRI image;
(iv) comparing the 3D bone shape measured from the first MRI image and the second MRI image, and determining responsiveness of the 3D bone shape change to the peptide injection; and
(v) repeating the injection until the pathological bone shape change in the joint is delayed or reduced, wherein the measuring and comparing of 3D bone shape are performed using active appearance modelling (AAM).